Abbott Diagnostics Quality System Violations Require Outside Audit By August
This article was originally published in The Gray Sheet
Executive Summary
Abbott's pending sale of its diagnostics business to GE will not be affected by an FDA warning letter citing quality control problems at its Irving, Texas, plant, the company claims
You may also be interested in...
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric
GE And Abbott Walk Away From $8 Billion Diagnostics Deal
Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric
Abbott Sells IVD, Point-Of-Care Diagnostics To GE For $8.13 Bil.
With GE's $8.13 billion cash purchase of Abbott Laboratories' core in vitro diagnostics unit Jan. 18, the corporate giant is betting it can accelerate growth in a business still recovering from protracted regulatory challenges in the U.S